FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology. There are prepared monomer and dimer domains VHH produced of camelids' antibodies able to bind the anti-rotavirus group A antigen VP6, as well as a method of detecting rotavirus group A, a composition for eliciting a passive immunity against rotavirus group A, a vector, cells and a method for producing the domain VHH of the invention, and a immunoassay kit for detecting rotavirus group A.
EFFECT: invention can find further application in preventing and treating rotaviral infections.
14 cl, 7 dwg, 5 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
VACCINE FOR PREVENTION AND TREATMENT OF ROTAVIRAL INFECTION CONTAINING HYBRID PROTEIN AS ACTIVE AGENT (VERSIONS) | 2013 |
|
RU2539913C2 |
VIRUS-LIKE CHIMERIC PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 CONTAINING CORONAVIRUS AND ROTAVIRUS PROTEINS | 2022 |
|
RU2779810C1 |
IMMUNOGLOBULIN WITH ONE VARIABLE DOMAIN AGAINST RSV F-PROTEIN | 2016 |
|
RU2730671C2 |
THERAPEUTIC POLYPEPTIDES, HOMOLOGUES THEREOF, FRAGMENTS THEREOF AND APPLICATION THEREOF FOR MODULATION OF PLATELET-MEDIATED AGGREGATION | 2004 |
|
RU2524129C2 |
ROTAVIRAL PARTICLES WITH CHIMERIC SURFACE PROTEINS | 2014 |
|
RU2698049C2 |
SINGLE-DOMAIN LLAMA ANTIBODY H5 AND ITS DERIVATIVE H5-Fc SPECIFICALLY BINDING THE RBD DOMAIN OF THE S-PROTEIN OF THE SARS-CoV-2 VIRUS POSSESSING VIRUS-NEUTRALIZING ACTIVITY | 2022 |
|
RU2793967C1 |
RECOMBINANT SINGLE-DOMAIN ANTIBODY ABLE TO BIND HUMAN TUMOUR NECROSIS FACTOR SPECIFICALLY AND ITS DERIVATIVES | 2012 |
|
RU2530553C2 |
IMMUNOBIOLOGICAL AGENT BASED ON VIRUS-LIKE PARTICLES FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST INFECTION CAUSED BY HUMAN ROTAVIRUS A | 2022 |
|
RU2795055C1 |
RECOMBINANT ANTIBODY SPECIFIC TO TUMOR NUCLEUS FACTOR AND MYELOID IMMUNE CELL MARKER | 2016 |
|
RU2652876C1 |
HIGH AFFINITY AND AGGREGATIONALLY STABLE ANTIBODIES BASED ON VL VARIABLE DOMAINS AND VHH DERIVATIVE | 2014 |
|
RU2609627C2 |
Authors
Dates
2013-08-20—Published
2008-07-24—Filed